ArticleThe Journal of allergy and clinical immunology2026
SERPINE1 promoter variants and differential airway responses to virus and biological therapy.
Article in The Journal of allergy and clinical immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
Abstract
backgroundA common functional promoter polymorphism (4G4G/4G5G) in the SERPINE1 gene, which encodes the plasminogen activator inhibitor 1 (PAI-1) protein, is associated with more frequent asthma exacerbations.
objectiveWe examined genotype-specific airway transcriptomic responses during viral illness and how genotype modulates these responses in asthma exacerbations with and without mepolizumab treatment.
methodsNasal lavage samples from a subset of children aged 6-17 years with exacerbation-prone asthma from the type 2-enriched urban asthma MUPPITS-1 and MUPPITS-2 cohorts were used for RNA sequencing and genetic studies. Expression quantitative trait locus (eQTL) analysis and weighted gene coexpression network analysis were performed to determine PAI-1 genotype modulation of gene expression during viral illness and genotype associations with mean expression levels of coexpressed networks of genes (modules). Linear regression analysis was performed to evaluate interactions between mepolizumab and the PAI-1 promoter variants.
resultsRisk genotypes were associated with lower SERPINE1 expression at baseline but higher levels over the course of viral illness (P < .02). In those with the risk allele at times of viral illness, there was increased expression of 4 coexpressed networks of genes including immune/Toll-like receptor signaling, and decreased expression of one network (ribosome). Subjects with the risk allele receiving mepolizumab with nonexacerbation viral illness had higher expression of eosinophil and mucus hypersecretion gene networks. In subjects with the risk allele receiving mepolizumab who experienced exacerbation, eosinophilic signaling networks were decreased, but gene networks involved in TGF-β/SMAD3 and perturbed epithelial integrity were increased compared to placebo. A number of drug-gene interactions were significant (P < .05, false discovery rate).
conclusionsNasal lavage SERPINE1 transcripts increase during viral illness in children with asthma who have the risk allele but not in children without this allele. In asthma exacerbations, the risk allele is associated with augmentation of TGF-β/SMAD3 and epithelial pathways as well as a differential airway transcriptomic response to the type 2 modulator mepolizumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.